# US 2025/0082597 A1 · Method for treating tauopathy in the brain, brain stem and spinal column

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082597 A1
- Document ID: US20250082597A1
- Status: Published application
- Kind: A1
- Application number: 18/956,321
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2013-01-25
- Assignees: Tedone 3G LLC
- Applicants: Tedone 3G LLC
- Inventors: Vincent M. Tedone
- Web page: https://patentgrep.com/patent/US20250082597A1

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 9/2095: {Tabletting processes}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

A composition of matter comprising an α-ketoglutarate (AKG) or an α-ketoglutaric acid or a salt of an α-ketoglutarate may be used to treat patients having a neurodegenerative disease, such as amyotrophic lateralsclerosis. The composition may be administered hourly or may be administered once a day depending on the size and activity of the patient and the release coating or mechanism provided. In addition to AKG, a core composition may comprise GABA and a source of coenzyme Q10. Other substances may be provided either orally or intravenous in addition to the core composition, as required to control symptoms, or in order to stimulate stem cells to add motor neurons.

## Claims

### Claim 1

A method of administering a nutritional supplement for the those suffering from a neurodegenerative disease characterized by tauopathy in the brain, brain stem and spinal column, comprising the steps of:
providing the nutritional supplement comprising a base composition with 3-9 grams of α-ketoglutarate and an amount of y-aminobutyric acid (GABA) of at least 50 mg and not more than 140 mg per serving of the composition, wherein the GABA has the chemical formula:
with a free amino group and a free carboxylic acid group when dissolved in water; and
taking the base composition orally three times per day as a supplement for a patient presenting with symptoms of a neurodegenerative disease characterized by tauopathy in the brain, brain stem or spinal column;
wherein the α-ketoglutarate of the base composition is selected such that the base composition effectively passes the blood brain barrier and treats the neurodegenerative disease in the brain, brain stem or spinal column at the dosage of the base composition when taken orally three times per day as a supplement; and
administering another a-ketoglutarate, in addition to the α-ketoglutarate of the base composition.

### Claim 2 (depends on 1)

The method of claim 1 wherein the a-ketoglutarate of the base composition comprises an arginine-α-ketoglutarate.

### Claim 3 (depends on 2)

The method of claim 2, wherein the another α-ketoglutarate does not comprise an arginine-α-ketoglutarate and is not combined with GABA.

### Claim 4 (depends on 2)

The method of claim 2, wherein the another α-ketoglutarate comprises a glycine-α-ketoglutarate and is not combined with GABA.

### Claim 5 (depends on 2)

The method of claim 2, wherein the another α-ketoglutarate comprises a magnesium-α-ketoglutarate and is not combined with GABA.

### Claim 6 (depends on 2)

The method of claim 2, wherein the α-ketoglutarate of the base composition further comprises a glycine-α-ketoglutarate.

### Claim 7 (depends on 6)

The method of claim 6, wherein the another α-ketoglutarate does not comprise an arginine-α-ketoglutarate and is not combined with GABA.

### Claim 8 (depends on 6)

The method of claim 6, wherein the another α-ketoglutarate comprises a glycine-α-ketoglutarate and is not combined with GABA.

### Claim 9 (depends on 6)

The method of claim 6, wherein the another α-ketoglutarate comprises a magnesium-α-ketoglutarate and is not combined with GABA.

### Claim 10 (depends on 2)

The method of claim 2, wherein the a-ketoglutarate of the base composition further comprises a magnesium-α-ketoglutarate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the another α-ketoglutarate does not comprise an arginine-α-ketoglutarate and is not combined with GABA.

### Claim 12 (depends on 10)

The method of claim 10, wherein the another α-ketoglutarate comprises a glycine-α-ketoglutarate and is not combined with GABA.

### Claim 13 (depends on 10)

The method of claim 10, wherein the another α-ketoglutarate comprises a magnesium-α-ketoglutarate and is not combined with GABA.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering the base composition in single serving packages.

### Claim 15 (depends on 14)

The method of claim 14, wherein the α-ketoglutarate of the base composition comprises an arginine-α-ketoglutarate.

### Claim 16

A method of preparing a nutritional supplement for the those suffering from a neurodegenerative disease characterized by tauopathy in the brain, brain stem and spinal column, comprising the steps of:
preparing a base composition comprising 3-9 grams of α-ketoglutarate and an amount of y-aminobutyric acid (GABA) of at least 50 mg and not more than 140 mg per serving of the composition, wherein the GABA has the chemical formula:
with a free amino group and a free carboxylic acid group when dissolved in water;
packaging the base composition in single serving packages, wherein the α-ketoglutarate of the base composition is selected such that the base composition effectively passes the blood brain barrier and treats the neurodegenerative disease in the brain, brain stem or spinal column at the dosage of the base composition when taken orally three times per day as a supplement; and
packaging another α-ketoglutarate, in addition to the α-ketoglutarate of the base composition, separate from the single serving packages of the base composition.

### Claim 17 (depends on 16)

The method of claim 16, wherein the α-ketoglutarate of the base composition comprises an arginine-α-ketoglutarate.

### Claim 18 (depends on 17)

The method of claim 17, wherein the another a-ketoglutarate does not comprise an arginine-α-ketoglutarate and is not combined with GABA.

### Claim 19 (depends on 17)

The method of claim 17, wherein the another α-ketoglutarate comprises a glycine-α-ketoglutarate and is not combined with GABA.

### Claim 20 (depends on 17)

The method of claim 17, wherein the another α-ketoglutarate comprises a magnesium-α-ketoglutarate and is not combined with GABA.
